How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

190 results for

Eosinophilic Cellulitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Tybost - cobicistat

Alternate Cause/Confounders Proposed Labeling 2434-8258 Diabetes mellitus (worsening) 2 No / Unlikely 10+ year history of DM; obesity None 0986-8285 Ovarian cyst Cervical dysplasia 1 2 No / No No / No Pre-existing conditions None None 4143-8442 Cervical dysplasia 3 No / No HPV None 2058-8335 Scrotal abscess Subcutaneous abscess 2 2 No / No No / No Circumcision None None 2734-8509 Perineal abscess/cellulitis Subcutaneous abscess 2 2 No / Unlikely No / Unlikely None None 3975-8443 Anal abscess 3 (...) initiating DRV/co and FTC/TDF. On Day 25 the reaction progressed to a diffuse erythematous rash, some angioedema, and pruritus at which time study drugs were discontinued. Liver enzymes, white blood cell count, and eosinophil count were normal. The next day, the subject had no oral lesions, blistering, or noticeable angioedema. The subject received antihistamines and prednisone, and the event resolved over a few days. The investigator assessed the event as Grade 3 and related to study medications

2014 FDA - Drug Approval Package

42. Adult Sinusitis Full Text available with Trip Pro

to diagnose and manage adults with rhinosinusitis and applies to any setting in which an adult with rhinosinusitis would be identified, monitored, or managed. This guideline, however, does not apply to patients younger than 18 years or to patients of any age with complicated rhinosinusitis. The guideline will not consider management of the following clinical presentations, although differential diagnosis for these conditions and bacterial rhinosinusitis will be discussed: allergic rhinitis, eosinophilic (...) . The importance of ABRS relates not only to prevalence but also to the potential for uncommon, but serious, complications that include meningitis, brain abscess, orbital cellulitis, and orbital abscess. , National ambulatory care data from 2006 to 2010 revealed that rhinosinusitis accounted for more outpatient antibiotic prescriptions than any other diagnosis. Despite guidelines that encourage judicious antibiotic use for ARS, , they are prescribed in about 82% of visits. From 2006 to 2010, rhinosinusitis

2015 American Academy of Otolaryngology - Head and Neck Surgery

43. Xeljanz (tofacitinib citrate)

routes were determined to be 500 mg/kg and >3 mg/kg, respectively, and the approximate lethal dose in monkeys by the oral route was determined to be >1000 mg/kg. In the rat oral study, the clinical signs included slow respiration, labored respiration, decreased activity, lethargy, and cold to the touch and clinical chemistry and histopathological changes included decreased eosinophils, increased BUN, decreased fibrinogen, increases in alanine aminotransferase (ALT), aspartate aminotransferase (AST (...) twice daily. 3.(iii).A.(2).1) Six-week oral toxicity study in rats (4.2.3.2.3) Male and female SD rats were orally administered tofacitinib at 0 (vehicle), 1, 10, or 100 mg/kg/day 12 for 6 weeks. Hematologic findings included reductions in eosinophil counts, lymphocyte counts, and red blood cell parameters, etc. at all dose levels and reductions in the percent reticulocytes, etc. at ?10 mg/kg/day. All parameters tended to recover over the 4-week recovery period and these findings were considered

2013 Pharmaceuticals and Medical Devices Agency, Japan

45. Dalbavancin hydrochloride (HCl) (Dalvance)

of therapy At 42-72 hours after initiation of treatment Primary efficacy endpoint population Clinically evaluable Intent-to-treat Area of cellulitis of >75cm 2 for all subtypes of infection Not required as an inclusion criterion Required as an inclusion criterion Subjects with urine output of 2x the upper limit of normal Excluded Allowed Reference ID: 3481080Clinical Review Dmitri Iarikov, MD, PhD NDA 21883, 505 (b)(1) DALVANCE (dalbavancin hydrochloride) 36 Table 8: Key differences in the design (...) enrolled in a North American study center, and 24 (3.7%) were enrolled in an Asian- Pacific study center. The distribution of the subjects by infection type in the ITT population in DUR001-301 and -302 trials as well as infection area baseline measurements are presented in the table on the following page. Cellulitis was the most common type of infection, diagnosed in more than 50% of dalbavancin- and comparator-treated subjects in both trials. There were somewhat more subjects with abscesses

2013 FDA - Drug Approval Package

51. Teriflunomide

% 10% Eosinophils > 0.5 Giga/L 8% 8% 12% Hemoglobin > 100 g/L- LLN 11% 13% 16% 160 mm Hg plus increase of 20 mm Hg 2% 4% 6% Diastolic > 110 mm Hg plus increase of 10 mm Hg 0.5% 2% 1.4% Weight The following chart displays the incidence of weight loss reported as an adverse event in Pool 1: Weight loss Placebo Ter 7 Ter 14 1% 3% 2% Reference ID: 3185084 21 The following chart displays the incidence of patients who experienced a potentially significant change in weight in Pool 1: Weight Placebo Ter 7

2012 FDA - Drug Approval Package

52. Conditioning SCID Infants Diagnosed Early

to antigen was not performed, but at least 4 of the following 8 supportive criteria, at least one of which must be among those marked with an asterisk (*) below are present, the patient is eligible as Omenn Syndrome. Hepatomegaly Splenomegaly Lymphadenopathy Elevated IgE Elevated absolute eosinophil count *Oligoclonal T cells measured by CDR3 length or flow cytometry (upload report) *Proliferation to PHA is reduced to < 50% of lower limit of normal (LLN) or SI < 30 *Low TRECs and/or percentage of CD4+/RA (...) a sterile site (e.g. blood, CSF, etc.): Repeat culture(s) from same site must be negative and patient has completed appropriate course of antibacterial therapy (typically at least 10 days). ii. Tissue-based clinical infection (e.g. cellulitis): Complete resolution of clinical signs (e.g. erythema, tenderness, etc.) and patient has completed appropriate course of antibacterial therapy (typically at least 10 days). iii. Pneumonia, organism not identified by bronchoalveolar lavage: Complete resolution

2018 Clinical Trials

55. British Association of Dermatologists' guidelines for the management of bullous pemphigoid

alone or associated with erythema and/or urti- cated plaques may precede formation of bullae by weeks or months;insomecasesbullaemaynotbecomeclinicallyapparent. 7.0 Diagnosis 7.1 Laboratory diagnosis of bullous pemphigoid A skin biopsy from a fresh blister stained with haematoxylin and eosin shows subepidermal clefting and an in?ammatory in?ltrate mainly consisting of eosinophils; however, the diag- nosis is con?rmed with immuno?uorescence studies (IF). A biopsy for direct IF (DIF) is taken from (...) also be caused by insect bites, burns, oedema, cellulitis, erythema multiforme and con- tact dermatitis. Viral and bacterial skin infections should be recognized and treated before treatment with immunosuppres- sant therapy is initiated. 8.0 Management BP is usually a self-limiting disease with a clinical course that may last from months to years. During the active stage, the disease is associated with signi?cant morbidity and a mortality twice that of the general elderly population. 3 Older age

2012 British Association of Dermatologists

56. Wells' Syndrome Successfully Treated with Colchicine Full Text available with Trip Pro

Wells' Syndrome Successfully Treated with Colchicine Eosinophilic cellulitis is an uncommon, inflammatory and chronic disorder of unknown etiology. Corticosteroids are currently considered as the first-line treatment but they are not without significant disadvantages such as contraindications in steroid-resistant cases and patients with frequent recurrences. We report a patient suffering from Wells' syndrome with a 24-year history of symptomatic and generalized skin lesions. After consultation

2017 Case reports in dermatology

57. Literature review - Twitter summary from #ACAAI18 meeting

of IgG level. Many of the links are via NFKb. Decreased NFKB1 phenotypes (AD, 60% penetrant): aphthous ulcers, Behcet-like and hypog (H67R); inflammatory GI tract disease and hypogam (I553M); NO hypogam, decreased switched B cells, necrotizing cellulitis (R157X). APDS1: sinopulmonary infections, LAN/splenomegaly, bronchiectasis/bronchitis/tracheal nodules, EBV/CMV, HSV, VZV infections; High IgM, IgM+ but not IgG+ B cells in tissue. CGD carriers can get disease like CGD lite, especially if DHR (...) improve survival in scleroderma. Asthma Dr. Li on asthma and lower respiratory diseases. Dupilumab was more effective for asthma if eosinophils were greater than 300. Eosinophilia can occur in 4.1% and hypereosinophilia 1.2% on dupilumab for asthma. Increased FeNO predicted better response to dupilumab. Dupilumab recently approved for moderate-severe asthma: if eosinophils are higher than 300 or FeNO is elevated, see better response to treatment with this biologic. Hypereosinophilia complication

2019 Allergy Notes blog

58. Literature review - Twitter summary from #ACAAI18 meeting

of IgG level. Many of the links are via NFKb. Decreased NFKB1 phenotypes (AD, 60% penetrant): aphthous ulcers, Behcet-like and hypog (H67R); inflammatory GI tract disease and hypogam (I553M); NO hypogam, decreased switched B cells, necrotizing cellulitis (R157X). APDS1: sinopulmonary infections, LAN/splenomegaly, bronchiectasis/bronchitis/tracheal nodules, EBV/CMV, HSV, VZV infections; High IgM, IgM+ but not IgG+ B cells in tissue. CGD carriers can get disease like CGD lite, especially if DHR (...) improve survival in scleroderma. Asthma Dr. Li on asthma and lower respiratory diseases. Dupilumab was more effective for asthma if eosinophils were greater than 300. Eosinophilia can occur in 4.1% and hypereosinophilia 1.2% on dupilumab for asthma. Increased FeNO predicted better response to dupilumab. Dupilumab recently approved for moderate-severe asthma: if eosinophils are higher than 300 or FeNO is elevated, see better response to treatment with this biologic. Hypereosinophilia complication

2019 Allergy Notes blog

59. Canadian clinical practice guidelines for acute and chronic rhinosinusitis

be urgently referred to a setting with appropriate imaging facilities and qualified specialty care. Red flags for urgent referral include: Systemic toxicity Altered mental status Severe headache Swelling of the orbit or change in visual acuity. Orbital and intracranial complications are the most feared complications of both acute and chronic rhinosinusitis. In the pre-antibiotic era, 20% of patients with orbital cellulitis went blind and 17% of patients died from intracranial sepsis [ ]. Even (...) in the current era, complications can result in permanent blindness or death if not treated appropriately and aggressively. Visual loss from sinusitis was reported at a rate of up to 10% in a 1991 study [ ]. Periorbital or orbital cellulitis is the most common complication of ABRS and most often caused by acute ethmoid and/or frontal disease [ , ]. Infection spreads from the sinuses to the orbit with relative ease [ , ]. Periorbital cellulitis is seen on CT as soft tissue swelling and manifests as orbital

2011 CPG Infobase

60. Chronic Leukemia

differentiated, usually B-lymphocytes, but immunologically incompetent; types distinguished include chronic granulocytic, chronic lymphocytic, chronic myelomonocytic, eosinophilic and hairy cell leukemia. Concepts Neoplastic Process ( T191 ) ICD9 208.1 ICD10 , , SnomedCT 92812005 , 2557004 , 128933000 , 190027002 , 188764001 , 154600002 English Leukemia of unspecified cell type, chronic , Chronic leukaemia NOS , Chronic leukemia NOS , Chronic leukaemia of unspecified cell type , Chronic leukemia (...) Leucémie chronique SAI , Leucémie à cellules de type non précisé, chronique , Leucémie chronique de type cellulaire non précisé , Leucémie chronique à cellules de type non précisé , Leucémie chronique German Leukaemie, chronisch , chronische Leukaemie eines unspezifischen Zelltyps , chronische Leukaemie NNB , Leukaemie eines unspezifischen Zelltyps, chronisch , Chronische Leukaemie nicht naeher bezeichneten Zelltyps , chronische Leukaemie Portuguese Leucemia crónica NE , Leucemia crónica de tipo

2018 FP Notebook

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>